Search

From April 22 to 25, the AFM-Telethon is organizing a major scientific congress at the Palais des Congrès in Paris. More than 1,100 experts in muscle and its diseases from all over the world will gather to review the latest advances in our knowledge of muscle (myogenesis, regeneration, fibrosis, aging, exercise, etc.) and our understanding of neuromuscular diseases, as well as the latest therapeutic innovations, particularly in gene therapy. 

Drugs in development or marketed with the support of AFM-Telethon concern neurological and neuromuscular diseases, diseases of the liver, vision, skin and immune system.

The impossible becomes possible! Thanks to the momentum of the Telethon and the work of researchers, a true scientific and medical revolution has begun and the first victories against rare diseases - previously incurable - have been won.  

The AFM-Téléthon sends you its best wishes for the New Year and hopes that 2024 will be full of scientific breakthroughs, small and large joys, and shared victories!

The Telethon 2023 ended on a high of €80,671,222, which shows the confidence and exceptional mobilization of donors and volunteers for this year's event, rich in victories against disease and promises for all those waiting for the diagnosis and treatment that will change their lives. We must not give up. 

Finding treatments for neuromuscular diseases by combining artificial intelligence, stem cells and pharmacological screening is the aim of the new DREAMS research consortium, coordinated by I-Stem. An unprecedented project!

Through its annual calls for proposals, each year AFM-Telethon supports new research projects in France and abroad, particularly for young researchers. After assessment by its Scientific advisory board, the Association finances the most relevant or most innovative initiatives in the development of therapeutic concepts and the understanding of the causes of rare and neuromuscular diseases. Discover its calls for proposals and financing opportunities. 

The 2024 edition of the International Consortium on Myotonic Dystrophy (IDMC-14) will take place in Nijmegen from 9 to 13 April 2024. This is an opportunity to learn, share and network thanks to the presence of scientists, clinicians, patients and professionals from the pharmaceutical industry. 

A gene therapy developed at Genethon by Ana Buj Bello's team is proving effective in a rare and very severe muscle disease: myotubular myopathy. Review of the results published online in The Lancet Neurology on November 15. 

Documents to discover everything about the latest progress in research for a given disease or group of diseases. See the publications in English. 

The 8th edition of international congress dedicated to neuromuscular science, MYOLOGY 2024, will take place in Paris from 22 to 25 April 2024. Registration and call for abstract are now open : don't miss an opportunity to showcase your latest study to an international community of scientists and healthcare professionals. The deadline for abstract submission has been extended until November 30, 2023 - 11:59 pm.

The first clinical results of the gene therapy for the treatment of limb-girdle muscular dystrophy type 2I/R9 show good preliminary efficacy and biological tolerability. These first results have been presented during oral communications during the 30th Annual Congress of the European Society of Gene & Cell Therapy (ESGCT) and will be presented in the 2023 International Limb-Girdle Muscular Dystrophy Conference in Washington DC.

A review published by two researchers at I-Stem, one of the AFM-Téléthon laboratories, takes stock of human pluripotent stem cells (hiPS) and confirms their main advantages in neuromuscular diseases: improving understanding and identifying new treatments.

The 30th of September is Limb-Girdle Muscular Dystrophy Awareness Day. At this occasion, the LGMD Interest Group of the AFM-Téléthon is planning an information day about these diseases in Evry.